Shouyao Holdings (Beijing) Co., Ltd, a biopharmaceutical company headquartered in Beijing and listed on the Shanghai Stock Exchange (SHA: 688197), has announced that it has obtained clinical trial approval for its drug candidate SY-7166 for the treatment of multiple myeloma (MM) as a monotherapy.
SY-7166 is a highly potent and selective immunoproteasome inhibitor that has demonstrated robust anti-tumor activity coupled with a favorable safety profile in pre-clinical evaluations. The drug candidate has exhibited significant inhibitory effects on both multiple myeloma and bortezomib-resistant multiple myeloma, suggesting that it may be effective as a standalone therapy or in combination with other treatments. It is anticipated that SY-7166 will yield promising clinical outcomes in the treatment of MM in upcoming clinical studies, while also enhancing safety and patient compliance.- Flcube.com
